Suppressor of cytokine signaling-3 (SOCS3) is an inducible inhibitor of cytokine signaling \[[@bib1], [@bib2]\]. SOCS3 is induced by various cytokines including IL-6 family cytokines such as leptin and IL-6 \[[@bib3]\]. Cytokines stimulate SOCS3 induction primarily via the Janus kinases (JAKs) and the signal transducers and activators of transcriptions (STATs) pathway. Induced SOCS3 inhibits cytokine signaling via the inhibition of JAK activity and targets the receptor complex for proteasomal degradation \[[@bib4]\]. Thus, SOCS3 is thought to limit the signaling cascade to prevent an excessive, aberrant response of cytokines.

SOCS3 in the hypothalamus has emerged as a critical regulator of energy balance \[[@bib4]\]. SOCS3 is significantly induced in the hypothalamus in response to high-fat diet feeding, pregnancy, aging, and long-day photoperiod that promotes positive energy balance \[[@bib5], [@bib9]\]. Forced expression of SOCS3 in a distinct population of hypothalamic neurons promoted body weight gain and adiposity \[[@bib10]\]. Consistently, induction of the constitutively active form of STAT3 in pro-opiomelanocortin neurons stimulated *Socs3* expression and increased body weight \[[@bib11]\]. In contrast, brain-specific *Socs3* knockout or its haploinsufficiency mice were significantly protected against the development of diet-induced obesity \[[@bib6], [@bib7]\]. Furthermore, the range of hypothalamic neuron-specific *Socs3* deletion mouse models demonstrates that hypothalamic Socs3 critically regulates body weight and glucose homeostasis \[[@bib12]\]. Thus, the level of *Socs3* expression in the hypothalamus seems to determine body weight and adiposity *in vivo*.

The effects of hypothalamic Socs3 on energy homeostasis seem to be at least in part mediated through inhibiting leptin actions. Leptin rapidly induces *Socs3* expression in the hypothalamus \[[@bib15]\]. Increased *Socs3* expression leads to the attenuation of cellular signaling of leptin in cultured cells and in animals in a cell-autonomous manner \[[@bib10], [@bib16], [@bib17]\]. In contrast, *Socs3* deficiency enhances cellular and physiological responses to exogenous leptin \[[@bib6], [@bib7]\]. Thus, it is well established that Socs3 is a negative feedback inhibitor of leptin *in vivo*. Signaling mechanisms mediating leptin-induced Socs3 involve the JAK-STAT3 pathway \[[@bib15], [@bib18]\]. In addition, recent studies have suggested the existence of a leptin-STAT3-independent mechanism. For example, STAT3 deficiency within leptin receptor (LepR)-expressing hypothalamic cells did not decrease mRNA expression of *Socs3* in LepR cells \[[@bib21]\]. Along the same line, inactivation of *Socs3* in LepR cells displayed a minimum effect on body weight \[[@bib14]\]. An increase of *Socs3* in LepR neurons does not cause obesity \[[@bib10]\]. Clearly, additional work is needed to elucidate signaling networks responsible for *Socs3* expression.

*Socs3* is also induced by other signaling pathways. *Socs3* expression is increased in response to stimulation with inflammatory signals such as Toll-like receptor 4 \[[@bib22]\], TNF-*α* \[[@bib23]\], and IL-1*β* \[[@bib23]\] that commonly activate the inhibitor of *κ* B kinase/nuclear factor *κ*B (NF-*κ*B) pathway \[[@bib2], [@bib24]\]. Indeed, activation of the NF-*κ*B pathway is sufficient to induce *Socs3* in the hypothalamus and elicit hypothalamic resistance to exogenous leptin \[[@bib17]\]. In addition, numerous studies demonstrate that cAMP plays a role to downregulate IL-6 signaling as well as to induce Socs3 in various cell types \[[@bib25]\]. Importantly, cAMP-elevating agents were reported to diminish cellular sensitivity to exogenous leptin in endothelial cells \[[@bib30]\] and in the hypothalamus \[[@bib31]\]. These findings raise a possibility that a molecular pathway of Socs3 induction might also interfere with cellular leptin actions. However, the signaling networks that confer the control of Socs3 levels and leptin sensitivity remain to be fully established. Therefore, delineation of molecular pathways responsible for Socs3 induction is of high interest. To facilitate the identification of such molecular pathways, we generated a new *Socs3*-luciferase reporter mouse (*Socs3*-Luc) and used hypothalamic explants of *Socs3*-Luc to search for and characterize a signaling pathway that influences *Socs3* expression and cellular leptin action *ex vivo*.

1. Materials and Methods {#s1}
========================

A. Generation of *Socs3*-Luc Mice {#s2}
---------------------------------

A 98.6-kb bacterial artificial chromosome (BAC; bMQ-126K3; Source BioScience) contains the entire *Socs3* gene locus. Luciferase2 cDNA was prepared from pGL4.10 (Promega, Madison, WI). The luciferase2 cDNA was introduced into the translation start site of the *Socs3* gene in the BAC clone in *Escherichia coli* cells using BAC recombineering techniques \[[@bib32]\]. The recombinant *Socs3* luciferase (*Socs3*-Luc) BAC DNA was prepared by NucleoBond Xtra BAC Kit (Macherey-Nagel, Germany), linearized by PI-SceI digestion, purified with phenol-chloroform, and precipitated with ethanol. Transgenic mice were obtained by injecting the linearized *Socs3*-luciferase BAC DNA into pronuclei of C57BL/6 mice in the Genetically Engineered Mouse Core at Baylor College of Medicine. *Socs3*-Luc founders were maintained at a C57BL/6 background. Tail biopsies were used for the genotyping on PCR with primers TL luciferase-F6 5′-CTTCGAGCAGACATGATAAGATAC-3′ and MFSOCS3-F1 5′-TGACGCTCAACGTGAAGAAG-3′ producing the amplicon of 591-bp long. The Institutional Animal Care and Use Committee at Baylor College of Medicine approved all procedures to maintain and use these mice.

B. Protein Extraction and Luciferase Assay {#s3}
------------------------------------------

*In vitro* luciferase activity was quantified using the Luciferase Assay System (Promega, Madison, WI). Tissues were extracted using the 1× Luciferase Cell Culture Lysis Reagent (Promega, Madison, WI), sonicated and vortexed, followed by centrifugation for 10 minutes at 4°C and 15,000 rpm. Supernatant was placed in a new 1.5-mL tube and stored at −80°C. To assess luciferase activity, 4 µL of sample was mixed with 20 µL Luciferase assay reagent, and luminescence was measured using a luminometer (Promega, Madison, WI). The Promega Luc-0-INJ protocol was used to measure luciferase activity in the tissues.

C. In Vivo Imaging {#s4}
------------------

Whole body imaging of luciferase activity *in vivo* was monitored using an In Vivo MS FX PRO imaging system (Bruker, Billerica, MA). Male and female mice were injected IP with 150 mg/kg body weight of d;-luciferin solution (Promega, Madison, WI) and anesthetized (2.5% isoflurane). Mice were transferred to nose cones within the chamber and imaged 10 minutes after injection of D-luciferin. Exposure time was 10 seconds on the ventral side, and luminescence was quantified using the Bruker imaging software. Bright-field images were also taken of mice with an exposure time of 5 seconds. Tissues, collected from male mice, were also imaged using the In Vivo MS FX PRO. Briefly, male mice were injected IP with 150 mg/kg body weight of D-luciferin solution and dissected 10 minutes later. Tissues were placed in chamber and bright-field, and luminescence images were taken using the same exposure times for *in vivo* imaging.

D. Organotypic Slice Experiments {#s5}
--------------------------------

Screening of compounds was accomplished using an organotypic slice culture system. Hypothalamic slices were made essentially as described before \[[@bib31]\]. Briefly, C57BL/6 mice male and female pups, 8 to 12 days old, were decapitated, and the brains were quickly removed. Hypothalamic tissues were blocked and sectioned in depth of 250 μm on a vibratome (VT1000S, Leica) in chilled Gey's Balanced Salt Solution (Invitrogen, Carlsbad, CA) enriched with glucose (0.5%) and KCl (30 mM). The coronal slices containing the arcuate nucleus were then placed on Millicell-CM filters (Millipore, pore size 0.4 μm, diameter 30 mm), and maintained at an air-media interface in MEM (Invitrogen, Carlsbad, CA) supplemented with heat inactivated horse serum (25%, Invitrogen, Carlsbad, CA), glucose (32 mM) and GlutaMAX (2 mM, Invitrogen, Carlsbad, CA). Cultures were typically maintained for 10 days in standard medium, which was replaced three times a week. After 10 days, the slices were used for experiments. The following modifications were made for *Socs3*-luc slices: after brains were sectioned, all sections were cut to the same diameter before being placed on Millicell-CM filters in culture. Slices were maintained 1 to 7 days in standard medium before being transferred to individual cell culture petri dishes (Thermo Fisher Scientific, Waltham, MA) containing low-serum (2% heat inactivated horse serum) phenol-red free MEM supplemented with glucose (32 mM) GlutaMAX (2 mM), 10% HEPES buffer (Invitrogen, Carlsbad, CA), and 0.1 mM d-luciferin. Dishes were sealed with a circular cover glass (Thermo Fisher Scientific, Waltham, MA) using vacuum grease (VWR, Radnor, PA) and placed in a Lumicycle 32 (Actimetrics, Wilmette, IL), a 32-channel luminometer at 37°C to measure luminescence from tissues. Treatments were added 2 days after slices were placed in the Lumicycle. Luciferase activity was analyzed using Lumicycle Analysis software.

E. Reagents {#s6}
-----------

We used the following reagents: lipopolysaccharide (LPS; L4391, Sigma-Aldrich, St. Louis, MO); IL-6 (RMIL6I, Thermo Fisher Scientific, Waltham, MA), IL-1*β* (I5271, Sigma-Aldrich St. Louis, MO); TNF-*α* (RMTNFAI, Thermo Fisher Scientific, Waltham, MA); forskolin (\#1099, TOCRIS, Bristol, United Kingdom); LY2090314 (SML1438, Sigma-Aldrich); CHIR99021 (SML1046, Sigma-Aldrich St. Louis, MO); methyl 3- 4methylphenyl sulfonyl amino benzoate (MSAB; M60316, Xcess Biosciences, San Diego, CA); and FH535 (S7484, SelleckChem, Houston, TX).

F. Quantitative RT-PCR {#s7}
----------------------

Tissues were quickly removed and frozen in liquid nitrogen and kept in −80°C until further processing. Total RNA was extracted using the RNeasy Lipid Tissue Kit (QIAGEN Sciences, Germantown, MD). cDNA was generated by iScript RT Supermix (Bio-Rad Laboratories, Hercules, CA) and used with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) for quantitative real-time PCR analysis. Quantitative PCR assays were performed using a CFX384 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). Normalized mRNA levels were expressed in arbitrary units obtained by dividing the averaged, efficiency-corrected values for sample mRNA expression by that of 18SrRNA expression for each sample. The resulting values were expressed as fold change above average control levels. The primer sequences are as follows: SOCS3 (F-CACCTGGACTCCTATGAGAAAGTG and *R*-GAGCATCATACTGATCCAGGAACT), PTP1B (F-GGAACAGGTACCGAGATGTCA and *R*-AGTCATTATCTTCCTGATGCAATT), TCPTP (F-AGGGCTTCCTTCTAAGG and *R*-GTTTCATCTGCTGCACCTTCTGAG), and 18SrRNA (F- CACGGACAGGATTGACAGATT and *R*-GCCAGAGTCTCGTTCGTTATC).

G. Immunohistochemistry {#s8}
-----------------------

For organotypic slices, slices were fixed overnight in 4% paraformaldehyde at 4°C. Then slices were cut out from the membrane and rinsed three times for 10 minutes each in PBS, pH 7.4 and then for 20 minutes in 1% hydrogen peroxide and 1% sodium hydroxide in PBS to quench endogenous peroxidase activity. Following a series of washes with PBS, slices were incubated for 48 to 72 hours at 4°C in pSTAT3 antibodies (1: 3000, 9131, Cell Signaling Technology, Boston, MA) \[[@bib33]\] in 3% normal donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA) with 0.25% Triton X-100 in PBS and 0.02% sodium azide. After washing in PBS, slices were incubated in a biotinylated goat antirabbit antibody IgG (1:1000, BA-1000, Jackson ImmunoResearch Laboratories West Grove, PA) \[[@bib34]\] in 3% donkey serum in 0.25 % Triton X-100 in PBS for 1 hour at room temperature. Tissues were then rinsed in PBS and incubated in the avidin-biotin-peroxidase complex kit (1:500, Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) for 1 hour. Slices were washed in PBS then reacted in 3,3′-diaminobenzidine (DAB; Sigma-Aldrich St. Louis, MO). Slices were then rinsed in PBS and mounted on slides using Vectashield (Vector Laboratories Burlingame, CA). For fluorescence staining, slices were incubated with Streptavidin, Alexa Fluor™ 488 conjugate (Molecular Probes, Eugene, OR). Immunohistochemical images were analyzed using a bright-field Leica microscope. To measure pSTAT3 signal in the arcuate nucleus, uneven background was eliminated with Adobe Photoshop and then intensity of DAB staining was measured.

H. Statistics {#s9}
-------------

The data are presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism for a two-tailed unpaired Student *t* test or one- or two-way ANOVA followed by *post hoc* Tukey, Bonferroni, or Sidak tests. *P* \< 0.05 was considered to be statistically significant.

2. Results {#s10}
==========

A. Generation and Characterization of *Socs3* Luciferase Reporter Mice {#s11}
----------------------------------------------------------------------

To create an *in vivo* monitoring system for endogenous *Socs3* expression in a noninvasive manner, we generated transgenic mice (*Socs3*-Luc) by engineering a *Socs3* BAC such that Luciferase2 gene is driven by *Socs3* regulatory elements ([Fig. 1A--1C](#fig1){ref-type="fig"}). The firefly luciferase-polyA was inserted into the ATG site of the *Socs3* gene in a 93.6-kb BAC containing the entire *Socs3* gene locus via homologous recombination, and transgenic mice were generated by pronuclear injection of the modified BAC. Transgenic founders and their offspring were identified by PCR ([Fig. 1B](#fig1){ref-type="fig"}). With the use of an *in vivo* imaging system, we functionally validated *Socs3*-Luc transgenic mice by monitoring luciferase activity in the reporter mice. *In vivo* luciferase imaging detected robust luciferase signals in *Socs3*-Luc but not in wild type (WT) mice ([Fig. 1C](#fig1){ref-type="fig"}). Analyzing luciferase activity of tissue lysates from liver and hypothalamus known to express *Socs3* we further confirmed that luciferase activity, normalized to the amount of total protein, was specifically detected only in tissues of *Socs3*-Luc mice ([Fig. 1D](#fig1){ref-type="fig"}).

![Generation of *Socs3*-Luc mice. (A) Schematic of the *Socs3*-Luc transgene. The full-length luciferase gene was inserted into the ATG codon of the *Socs3* gene in a BAC (bMQ126k03). (B) *Socs3*-Luc mice were identified by PCR analysis. (C) Live imaging of luciferase activity in WT and *Socs3*-Luc mice. (D) Luciferase enzymatic activity in liver and hypothalamus of WT and *Socs3*-Luc mice.](js.2019-00077f1){#fig1}

Next we examined whether the reporter mice respond to LPS endotoxin \[[@bib22]\] that activates a potent, common proinflammatory response and is known to induce *Socs3* \[[@bib2]\]. We injected LPS into the periphery of *Socs3*-Luc mice and their littermate controls (WT) and measured luciferase activity using the *in vivo* imaging system. Total body luciferase activity was markedly stimulated in the *Socs3*-Luc mice 4 hours after LPS administration, whereas luciferase activity was low in vehicle-injected animals ([Fig. 2A](#fig2){ref-type="fig"}). To assess the tissue distribution of luciferase luminescence detected in *Socs3*-Luc, we dissected internal peripheral organs including small intestine, liver, spleen, kidney, stomach, pancreas, white adipose tissue, brown adipose tissue and heart, at 4 hours after the LPS administration and measured their luciferase activity using in vivo imaging system analysis. Almost all of the tissue samples showed some level of luciferase luminescence induced by LPS ([Fig. 2B](#fig2){ref-type="fig"}). We also determined if the *Socs3* luciferase reporter recapitulates LPS-induced gene expression pattern of *Socs3* mRNA by measuring *in vitro* biochemical luciferase activity and endogenous *Socs3* mRNA in various tissues of *Socs3*-Luc mice with or without LPS injection. The basal levels of luciferase activities in tissue lysates were detected in all tissues we examined with relatively high *in vitro* luciferase activity from liver, stomach, muscle, and spleen ([Fig. 2C](#fig2){ref-type="fig"}). Upon LPS treatment, the highest induction of luciferase activity was found in intestine, pancreas, kidney, and liver, whereas it was moderate in brain tissues, fat tissues, stomach, and muscle ([Fig. 2D](#fig2){ref-type="fig"}). We found a close correlation between luciferase activity and endogenous *Socs3* mRNA expression ([Fig. 2D and 2E](#fig2){ref-type="fig"}). Endogenous *Socs3* mRNA expression was remarkably induced in most of the tissues in an LPS-dependent manner ([Fig. 2E](#fig2){ref-type="fig"}). In particular, liver, kidney, stomach, heart, intestine, and pancreas showed highly induced expression of the endogenous *Socs3* ([Fig. 2E](#fig2){ref-type="fig"}), which closely correlated with the induced expression pattern of the luciferase luminescence. These data thus demonstrate that the *Socs3* reporter model faithfully mirrors the tissue distribution of endogenous *Socs3* mRNA *in vivo*.

![Functional validation of *Socs3*-Luc mice. (A) Luminescence images of *Socs3*-Luc mice intraperitoneally administered with either saline or 100 ng/kg LPS for 4 h. (B) Bright field images (left) and bioluminescence images (right) of various tissues of *Socs3*-Luc mice receiving LPS (100 ng/kg for 4 h) or saline. (C and D) *In vitro* luciferase activity of the indicated tissue lysates extracted from mice treated with either (C) saline or (D) 100 ng/kg LPS for 4 h shown as bioluminescent signal. The same amount of protein (3.5 µg) was used for each reaction. (E) *Socs3* mRNA in various tissues of the mice treated with either saline or 100 ng/kg LPS for 4 h. Data are mean ± SEM; n = 3 to 4/per group. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\*\**P* \< 0.0001 vs control based on *t* tests.](js.2019-00077f2){#fig2}

B. An Ex Vivo Model to Monitor Hypothalamic *Socs3* Expression {#s12}
--------------------------------------------------------------

Hypothalamic levels of Socs3 crucially regulate energy balance \[[@bib5], [@bib35]\]. To explore signaling mechanisms by which hypothalamic Socs3 levels are determined, we used hypothalamic explants of *Socs3*-Luc mice that allow us to pharmacologically manipulate various signaling cascades and rapidly assess its effect on *Socs3* expression. Mediobasal hypothalamus was dissected and placed on a membrane in a dish containing media supplemented with luciferin substrate. Hypothalamic explants were treated with chemicals and peptides, and luminescence was continuously measured in real time with photomultiplier tube detectors during the treatment ([Fig. 3A](#fig3){ref-type="fig"}). To confirm that the *Socs3* luciferase reporter hypothalamic slice is capable of responding to LPS, we treated slices with LPS and luminescence was continuously measured in real time. As shown in [Fig. 3B](#fig3){ref-type="fig"}, slices treated with LPS show a 3.0-fold increase in luciferase activity compared with their PBS controls. Because Socs3 is also produced by proinflammatory cytokines that include IL-6, TNF-*α*, and IL-1*β* \[[@bib22], [@bib23]\], slices were treated with them to further validate our *ex vivo* model. As expected, all three of the cytokines tested resulted in an increase in luciferase activity ([Fig. 3C--3E](#fig3){ref-type="fig"}). Forskolin, a previously reported inducer of *Socs3* in various cells, also displayed a 2.4-fold increase in luciferase activity in hypothalamic explants ([Fig. 3F](#fig3){ref-type="fig"}). These results confirm that hypothalamic slices prepared from *Socs3*-Luc mice can serve as a suitable screening tool for measuring the effects of modulators of *Socs3* expression in the hypothalamus.

![Hypothalamic slice cultures as a screening tool for hypothalamic *Socs3* modulators. (A) Screening scheme. Hypothalamic slice cultures were made from 8- to 12-d-old *Socs3*-Luc mice, and luciferase activity of slices was monitored with a Lumicycle 32 following compound treatment. (B--F) Using hypothalamic slice culture, *Socs3* luciferase signal was probed *ex vivo* using known inducers of *Socs3*. Data are mean ± SEM; n = 3 to 4 per group. \*\**P* \< 0.01; \*\*\*\**P* \< 0.0001 vs control based on two-way ANOVA. FSK, forskolin.](js.2019-00077f3){#fig3}

C. Inhibitors of Glycogen Synthase Kinase-3β Induces *Socs3* Gene Expression in the Hypothalamus {#s13}
------------------------------------------------------------------------------------------------

With the use of the *ex vivo* model to screen compounds for their ability to alter *Socs3* expression, we came upon chemicals that target proteins involved in the glycogen synthase kinase-3 (GSK3)*β*―*β*-catenin signaling pathway. First, we found that treatment with GSK3 inhibitor LY2090314 \[[@bib36]\], a potent and selective small-molecule inhibitor of GSK3*α* and GSK3*β* isoforms, induces a 2.1-fold increase in luciferase activity and this occurs in a dose-dependent manner ([Fig. 4A and 4B](#fig4){ref-type="fig"}). Consistently, the mRNA level of endogenous *Socs3* was elevated in slices treated with LY2090314 ([Fig. 4C](#fig4){ref-type="fig"}). Interestingly, we did not detect any increases in other inhibitors of cytokine signaling such as tyrosine protein phosphatases. Hypothalamic induction of *Socs3* was also observed in explants treated with CHIR99021 \[[@bib37]\], a well-established specific inhibitor for GSK3*β* with a different kinase selectivity profile than LY2090314 ([Fig. 4D and 4F](#fig4){ref-type="fig"}). This increase also occurred in a dose-dependent manner [Fig. 4E](#fig4){ref-type="fig"}. These data clearly suggest that pharmacologic inhibition of GSK3*β* stimulates *Socs3* gene expression in the hypothalamus.

![Inhibitors of GSK3*β* increase *Socs3* expression in hypothalamus *ex vivo*. (A) Luminescence signal observed in *Socs3*-Luc slices treated with CHIR99021 (10 μM) or dimethyl sulfoxide (DMSO) control. (B) Dose response of CHIR99021 in explants of *Socs3* Luc mice. (C) Expression of *Socs3*, *Ptp1b*, and *Tcptp* in hypothalamic slices treated with CHIR99021 (10 μM) or DMSO control for 20 h. (D) Luminescence signal observed in *Socs3*-Luc slices treated with LY2090314 (10 nM). (E) Dose response of LY2090314 in explants of *Socs3*-Luc mice. (F) Expression of *Socs3*, *Ptp1b*, and *Tcptp* in hypothalamic slices treated with LY2090314 (10 nM) or DMSO control for 20 h. CHIR99021 and LY2090314, GSK3*β* inhibitors; Data are mean ± SEM; n = 3 to 4 per group. \*\*\*\**P* \< 0.0001 for two-way ANOVA (in A and D); \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 for one-way ANOVA followed by Tukey multiple comparisons test (in B and E); \*\* *P* \< 0.01, \*\*\**P* \< 0.001 vs control based on *t* tests (in C and F).](js.2019-00077f4){#fig4}

D. Inhibitors of β-Catenin Decrease *Socs3* Gene Expression in the Hypothalamus {#s14}
-------------------------------------------------------------------------------

Next, we explored the mechanism by which GSK3*β* inhibition increased *Socs3* transcription. Because GSK3*β* acts through *β*-catenin \[[@bib38]\], we hypothesized that the action of GSK3*β* inhibitors in hypothalamus could be mediated through *β*-catenin. To test this, *Socs3*-Luc slices were treated with FH535 (50 µM) \[[@bib39]\], an inhibitor of *β*-catenin. This treatment resulted in a decrease in luciferase activity in a dose-dependent manner ([Fig. 5A and 5B](#fig5){ref-type="fig"}). Because FH535 is not a selective inhibitor of *β*-catenin \[[@bib39]\], we further tested a more specific *β*-catenin inhibitor MSAB \[[@bib40]\] for its ability to decrease *Socs3* luciferase signal. Similar to FH535, treating slices with MSAB significantly decreased *Socs3* luciferase activity, and this decrease was also dose-dependent ([Fig. 5C and 5D](#fig5){ref-type="fig"}). These data suggest that inhibition of *β*-Catenin induces *Socs3* gene expression.

![Inhibitors of *β*-catenin, downstream of GSK3*β*, decrease *Socs3* expression. (A) Luminescence signal observed in *Socs3*-Luc slices treated with FH535 (50 µM) relative to DMSO control. (B) Dose response of FH535 in *Socs3*-Luc slices. (C) Luminescence signal observed in *Socs3*-Luc slices treated with MSAB (500 μM) relative to DMSO control. (D) Dose response of MSAB in *Socs3*-Luc slices. Data are mean ± SEM; n = 3 to 4 per group. \*\*\*\**P* \< 0.0001 for two-way ANOVA (in A, C, and E); \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs control for one-way ANOVA followed by Tukey multiple comparisons test (in B and D).](js.2019-00077f5){#fig5}

E. A GSK3β Inhibitor Blocks Leptin-Induced STAT3 Phosphorylation in Hypothalamic Slices {#s15}
---------------------------------------------------------------------------------------

SOCS3 potently limits cellular leptin signaling in the hypothalamus. To examine the functional consequences of GSK3*β* inhibition, we examined if the treatment desensitizes the hypothalamic cells to leptin using *ex vivo* hypothalamic slices that recapitulate hypothalamic leptin signaling \[[@bib31]\]. Hypothalamic slices were exposed to CHIR99021 (10 µM for 6 hours) followed by leptin stimulation (120 nM for 60 minutes) to examine the effects of GSK3*β* inhibition. Similar to previous observations, leptin robustly induced phosphorylation of STAT3 in control slices. In contrast, treatment of the slices with both CHIR99021 had a potent inhibitory effect on leptin-induced STAT3 phosphorylation in the hypothalamus ([Fig. 6A and 6B](#fig6){ref-type="fig"}). CHIR99021 alone had no effect on pSTAT3 ([Fig. 6A and 6B](#fig6){ref-type="fig"}). These data suggest that inhibition of GSK3*β* impairs hypothalamic LepR signaling.

![The effect of a GSK3*β* specific inhibitor on hypothalamic leptin signaling. (A) Immunohistochemistry of phosphorylated STAT3 (pSTAT3) in tissues treated with either DMSO or CHIR99021. Slices were pretreated with CHIR99021 (10 μM, 6 h) followed by leptin stimulation (120 nM, 60 min). After fixed with 4% formalin, slices were subjected to immunohistochemistry with anti-pSTAT3 antibodies followed by fluorescence visualization with Alexa Fluor-labeled secondary antibodies. (B) Quantification of hypothalamic pSTAT3. pSTAT3 signal was detected by DAB staining. Values are presented as mean ± SEM. Three separate experiments. \*\**P* \< 0.01, \*\*\*\**P* \< 0.0001 for two-way ANOVA followed by Sidak multiple comparisons test.](js.2019-00077f6){#fig6}

3. Discussion {#s16}
=============

SOCS3 plays a critical role in controlling inflammation and metabolism. SOCS3 levels appear to determine cellular sensitivity to cytokines and metabolic hormones, and SOCS3 gene expression is tightly controlled. However, the underlying signaling mechanisms are not fully established. To explore the mechanism of *Socs3* induction, we have generated *Socs3* reporter mice that allow us to quantitatively monitor changes in *Socs3* expression *in vivo*. We have also developed a hypothalamic slice-based compound screening platform to monitor hypothalamic *Socs3* expression. The tool provides an opportunity to identify signaling pathways that control *Socs3* expression in hypothalamus *ex vivo*.

Using the LPS-induced inflammation model that stimulates *Socs3* induction *in vivo* \[[@bib1], [@bib23], [@bib41]\], we validated if *Socs3*-Luc mice could recapitulate the LPS-induced robust induction of *Socs3*. *Socs3* luciferase activity was detected in almost all tissues among those examined after the LPS injection. Importantly, the tissue distribution pattern of LPS-induced luciferase signals closely correlates with that of endogenous *Socs3* mRNA. In accordance with the reported studies showing that *Socs3* induction emerges only after a few hours following the LPS injection *in vivo* \[[@bib42], [@bib43]\], we found that luciferase signals were observed at 4 hours, but not at 30 minutes after LPS injection in the *Socs3-Luc* transgenic mice (data not shown). This pattern of luciferase signals was observed in both whole-body mice and individual tissues we examined (small intestine, liver, spleen, kidney, stomach, pancreas, WAT, BAT, and heart). These results are consistent with previous studies that have shown peak expression levels of *Socs3* to be around 4 hours in liver and brain tissues \[[@bib42], [@bib43]\]. A number of studies have shown that LPS increase SOSC3 rapidly within several minutes in cells such as macrophages *in vitro* and *in vivo*. Although the exact reasons for this discrepancy remain unknown, this might be due to difference in the time frame of temporal response to LPS in different tissues. These observations underscore that the *Socs3* luciferase reporter model faithfully and robustly reports spatiotemporal dynamics of endogenous *Socs3* mRNA *in vivo*.

To establish a reliable *in vitro* monitoring system, we first developed a hypothalamic slice culture-based assay that allows real-time monitoring of *Socs3* expression using organotypic hypothalamic slices. The organotypic brain slice model is known to partly preserve the *in vivo* anatomy and function of the hypothalamus \[[@bib44]\]. Previous results from the studies by ours and other groups demonstrated that the slice model can genuinely recapitulate *in vivo* cellular responses to metabolic hormones, anatomically, biochemically, and electrophysiologically \[[@bib31], [@bib45]\]. In the current study, we show that the *ex vivo* system reliably reproduces hypothalamic responses to LPS, TNF-*α*, IL-1*β*, IL-6, and forskolin, which increase *Socs3* mRNA *in vivo* \[[@bib22], [@bib23], [@bib26]\]. All of the *Socs3* inducers remarkably elevated luciferase activity in *Socs3*-Luc hypothalamic explants. Thus, the *in vivo* and *ex vivo* data collectively suggest that luciferase activity serves as a genuine reporter for monitoring *Socs3* expression in real-time, and more importantly, this slice-based imaging model offers a feasible and reliable platform to search for small chemicals for *Socs3* expression *in vitro*.

With the use of the *ex vivo* monitoring model, we identified several compounds (CHIR99021, LY2090314, FH535, and MSAB) that lead to the modulation of *Socs3* expression in the hypothalamus. LY2090314 \[[@bib36]\], a potent and selective small-molecule inhibitor of GSK3*α* and GSK3*β* isoforms, clearly stimulated *Socs3* luciferase activity in the hypothalamic explants, suggesting that inhibition of GSK3 activity results in increased *Socs3* gene expression. Further, hypothalamic induction of *Socs3* was observed in explants treated with CHIR99021 \[[@bib37]\], a structurally distinct specific inhibitor for GSK3*β*. The effects of LY2090314 and CHIR99021 were observed in the nanomolar or micromolar range, respectively, which are within the effective concentrations established by various cell-based functional assays \[[@bib36], [@bib49], [@bib50]\]. GSK3*β* is known to be involved in several distinct signaling pathways such as cellular signaling mediating insulin, wingless and integration site growth factor, and hedgehog. GSK3*β* is constitutively active under unstimulated conditions where GSK3*β* phosphorylates *β*-catenin, which in turn is subjected to ubiquitin proteasome degradation. In contrast, inhibition of GSK3*β* by upstream signals such as wingless and integration site growth factor and insulin signaling results in an increase in *β*-catenin protein levels, which promotes the transcription of its target genes in a T-cell factor/lymphoid enhancer factor-dependent mechanism. Thus, pharmacological inhibition of GSK3*β* should also lead to activation of *β*-catenin-dependent gene expression. *Ex vivo* studies suggest that GSK3*β* inhibition-induced *Socs3* expression is mediated by *β*-catenin (data not shown), indicating a pathway that links GSK3*β* and Socs3 via *β*-catenin in the hypothalamus. The findings in the *ex vivo* studies presented in this paper provide evidence demonstrating that the GSK3*β*―*β*-catenin pathway might act as a potential regulator of *Socs3* expression in the hypothalamus.

One potential implication of our results is that GSK3*β* inhibition may downregulate cellular signaling of leptin via Socs3 induction. Several studies have shown that SOCS3 inhibits cellular actions of leptin by interfering with LepR signaling. Prior studies demonstrated that Socs3 is induced by several distinct signaling pathways that include the JAK-STAT3 pathway, the inhibitor of *κ* B kinase/NF-*κ*B pathway \[[@bib2], [@bib17], [@bib24]\], the endoplasmic reticulum stress-related pathways \[[@bib51]\], and the cAMP-related pathways \[[@bib30], [@bib31]\]. Notably, all of these pathways limit cellular leptin sensitivity, as well as induce Socs3 in the hypothalamus implicating that the pathways underlying *Socs3* induction would inhibit cellular signaling of leptin. Consistent with this notion, our studies indeed demonstrate that a specific inhibitor for GSK3*β* inhibited leptin-induced STAT3 phosphorylation, while inducing hypothalamic *Socs3*. The failure of exogenous leptin to modulate key signaling events such as STAT3 phosphorylation within hypothalamic neurons is well documented in various physiological and pathophysiological settings. These phenomena occur in response to high-fat diet feeding, chronic leptin exposure, pregnancy and lactation, age, and seasonal variations in the length of the photoperiod in seasonal animals. Under these conditions, Socs3 is commonly elevated and likely to play a role in suppressing leptin actions. Future studies are warranted to elucidate the role of the GSK3*β*―*β*-catenin pathway in Socs3 induction under these conditions.

In addition to leptin actions, SOCS3 commonly suppresses cellular signaling of inflammation. A number of studies have shown that inhibition of GSK3*β* has the ability to reduce inflammation. For example, GSK3*β* inhibition protects against LPS-induced endotoxin shock *in vivo*, decreases proinflammatory cytokine production, and interferes with NF-*κ*B and STAT3 pathways. At the molecular level, GSK3*β* inhibition was reported to affect the nuclear amounts of transcription factors NF-*κ*B subunit p65 and CREB interacting with the coactivator CBP \[[@bib52]\]. GSK3*β* was also shown to block STAT3 DNA binding activity and STAT3-dependent gene expression \[[@bib53]\]. These data suggest the ability of GSK3*β* inactivation to strongly induce *Socs3* and may add another mechanism by which GSK3 inactivation potently suppresses inflammation.

Because *Socs3* expression is altered dynamically under various biological conditions such as inflammation, dietary obesity, pregnancy and lactation, seasonal adiposity, intestinal bowel disease, ulcerative colitis, Crohn disease, rheumatoid arthritis, thymocyte differentiation, and atherosclerotic lesions \[[@bib5], [@bib35], [@bib54]\], this model may also facilitate the functional investigation of SOCS3 in multiple tissues and in diverse physiological and pathophysiological conditions.

In summary, we have created a BAC-transgenic luciferase reporter mouse carrying the *Socs3*-luciferase reporter in the *Socs3* genomic locus. These mice show robust Socs3 activity after administration of LPS *in vivo*, and hypothalamic explants derived from these animals can be used as a slice-based screening platform to identify signaling networks that alter hypothalamic *Socs3* expression.
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BAC

:   bacterial artificial chromosome

DAB

:   3,3′-diaminobenzidine

GSK3

:   glycogen synthase kinase-3

JAK

:   Janus kinases

LepR

:   leptin receptor

LPS

:   lipopolysaccharide

Luc

:   Luciferase

MSAB

:   methyl 3- 4methylphenyl sulfonyl amino benzoate

NF-*κ*B

:   nuclear factor *κ*B

SOCS3

:   suppressor of cytokine signaling-3

STAT3

:   signal transducers and activators of transcription 3

WT

:   wild type
